Andrew Boyer Net Worth

The estimated Net Worth of Andrew S Boyer is at least $5.87 Million dollars as of 14 August 2024. Mr. Boyer owns over 62,711 units of Amneal Pharmaceuticals Inc stock worth over $2,145,761 and over the last 7 years he sold AMRX stock worth over $612,672. In addition, he makes $3,113,080 as Executive Vice President - Commercial Operations at Amneal Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Boyer AMRX stock SEC Form 4 insiders trading

Andrew has made over 19 trades of the Amneal Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 62,711 units of AMRX stock worth $491,654 on 14 August 2024.

The largest trade he's ever made was exercising 120,316 units of Amneal Pharmaceuticals Inc stock on 1 March 2024 worth over $1,005,842. On average, Andrew trades about 26,741 units every 74 days since 2018. As of 14 August 2024 he still owns at least 256,670 units of Amneal Pharmaceuticals Inc stock.

You can see the complete history of Mr. Boyer stock trades at the bottom of the page.

Andrew Boyer biography

Andrew S. Boyer serves as Executive Vice President - Commercial Operations of the Company. Prior to joining Amneal, Mr. Boyer served as President & CEO of North America Generics, Teva Pharmaceutical Industries Ltd. from August 2016 to February 2018. Before that, Mr. Boyer was Senior Vice President of Sales and Marketing for the U.S. Generics Division at Allergan from September 2006 to August 2016. Mr. Boyer joined Allergan (then known as Watson Pharmaceuticals) in 1998 as Associate Director of Marketing in Generics. Before joining Allergan, Mr. Boyer served as National Accounts Manager for Lederle/American Cyanamid as well as Marketing Manager for Barr Laboratories. He serves as a Director of the Association for Accessible Medicines. Mr. Boyer received his bachelor’s degree in Business Administration and Management from State University of New York at Albany.

What is the salary of Andrew Boyer?

As the Executive Vice President - Commercial Operations of Amneal Pharmaceuticals Inc, the total compensation of Andrew Boyer at Amneal Pharmaceuticals Inc is $3,113,080. There are no executives at Amneal Pharmaceuticals Inc getting paid more.

How old is Andrew Boyer?

Andrew Boyer is 54, he's been the Executive Vice President - Commercial Operations of Amneal Pharmaceuticals Inc since 2018. There are 7 older and 12 younger executives at Amneal Pharmaceuticals Inc. The oldest executive at Amneal Pharmaceuticals Inc is Shlomo Yanai, 67, who is the Independent Director.

What's Andrew Boyer's mailing address?

Andrew's mailing address filed with the SEC is C/O AMNEAL PHARMACEUTICALS, INC., , BRIDGEWATER, NJ, 08807.

Insiders trading at Amneal Pharmaceuticals Inc

Over the last 7 years, insiders at Amneal Pharmaceuticals Inc have traded over $867,197,480 worth of Amneal Pharmaceuticals Inc stock and bought 3,818,425 units worth $12,997,905 . The most active insiders traders include Gp A, Llcbonderman Davidcou..., Holdings, Llc Aphc, and International Ltd Fosun. On average, Amneal Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $3,857,739. The most recent stock trade was executed by Andrew S Boyer on 14 August 2024, trading 62,711 units of AMRX stock currently worth $491,654.

What does Amneal Pharmaceuticals Inc do?

an american pharmaceutical company, amneal develops and produces affordable medicines. the company was built upon a family tradition of quality and integrity. everything amneal does, across the full spectrum of its business, is in service to these guiding principles. amneal is committed to constantly elevating and refining the value it delivers to its customers and patients around the globe.

Complete history of Mr. Boyer stock trades at Amneal Pharmaceuticals Inc

Amneal Pharmaceuticals Inc executives and stock owners

Amneal Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Andrew Boyer,
  Executive Vice President - Commercial Operations
• Chintu Patel R.Ph, R.Ph.,
  Co-Founder, Co-CEO & Director
• Nikita Shah,
  Chief Human Resource Officer, Senior Vice President
• Andrew S. Boyer,
  Exec. VP & Chief Commercial Officer of Generics
• Anastasios G. Konidaris,
  Exec. VP & CFO
• Joseph Todisco MBA,
  Exec. VP & Chief Commercial Officer of Specialty
• Nikita Shah,
  Exec. VP and Chief HR Officer & Strategic Planning Officer
• J. Kevin Buchi,
  Independent Director
• Ted Nark,
  Independent Director
• Emily Alva,
  Independent Director
• Gautam Patel,
  Director
• Chintu Patel,
  Co-Chief Executive Officer, Co-Founder, Director
• Chirag Patel,
  President, Co-Chief Executive Officer, Director
• Paul Meister,
  Independent Chairman of the Board
• Shlomo Yanai,
  Independent Director
• John Kiely,
  Independent Director
• Jeffrey George,
  Independent Director
• Chintu Patel R.Ph., R.Ph,
  Co-Founder, Co-CEO & Director
• Chirag K. Patel,
  Co-Founder, Co-CEO, Pres & Director
• Joseph Todisco,
  Senior Vice President - Specialty Commercial
• Apurva Saraf,
  Senior Vice President - Corporate Development
• Joseph Greer,
  Senior Vice President - Global Quality Management
• Stephen Manzano,
  Senior Vice President, General Counsel & Corporate Secretary
• Sanjay Jain,
  President - India
• Anastasios Konidaris,
  Chief Financial Officer, Senior Vice President
• Jason B. Daly Esq.,
  Sr. VP, Chief Legal Officer & Corp. Sec.
• Dr. Nikunj Patel,
  Head of Ops & Exec. VP of Amneal Pharmaceuticals (India) Pvt Ltd
• Sanjiv Patel,
  Sr. VP of Operations
• Stephen J. Manzano,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Anthony DiMeo,
  Sr. Director of Investor Relations
• Sheldon Hirt,
  SVP, GC & Corp. Sec.
• Jean Selden Greene,
  Director
• Holdings, Llc Aphc,
  10% owner
• Robert L Burr,
  Director
• Bryan M. Reasons,
  CFO
• Robert A Stewart,
  President and CEO
• Dharmendra Rama,
  Director
• Janet S. Vergis,
  Director
• Peter R Terreri,
  Director
• Paul Bisaro,
  Executive Chairman
• David A Buchen,
  SVP, Chief Legal Officer
• Todd P. Branning,
  SVP and CFO
• Pradeep Bhadauria,
  SVP, Chief Scientific Officer
• International Ltd Fosun,
  10% owner
• Gustavo Pesquin,
  See Remarks
• Gp A, Llcbonderman Davidcou...,
  
• Tasos Konidaris,
  Executive Vice President & CFO
• Jason B. Daly,
  SVP, Chief Legal Officer
• Deborah M. Autor,
  Director
• Dipan Patel,
  
• Tushar Bhikhubhai Patel,
  10% owner